Richard I. Morimoto - Morimoto's Science

Morimoto's Science

Morimoto is widely recognized for his research on the regulation of the heat shock stress response and the function of molecular chaperones. His current research is to understand how organisms sense and respond to physiologic and environmental stress through the activation of genetic pathways that integrate stress responses with molecular and cellular responses that determine cell growth and cell death. The stress of misfolded and damaged proteins influences neuronal function and lifespan at the level of the organism. Consequently, these studies provide a molecular basis to elucidate the underlying mechanisms of neurodegenerative diseases including Huntington's disease, Parkinson's disease, ALS, and Alzheimer's disease. His laboratory has published over 200 papers including three monographs including two books on the Heat Shock Response and Molecular Chaperones from Cold Spring Harbor Press. During that period he received a MERIT award from the National Institutes of Health and has been supported by the grants from the National Institutes for General Medical Science, National Institutes of Aging, National Institutes for Neurological Diseases and Stroke, American Cancer Society, Huntington's Disease Society of America, the Hereditary Disease Foundation, and the ALS Association. In addition to giving frequent talks at universities and scientific symposia throughout the world, he has been a Visiting Professor at the Technion University in Israel, Osaka University, Kyoto University, University of Rome, Beijing University, Åbo Akademi University in Finland, and École Normale Supérieure in Paris. He is a founder of Proteostasis Therapeutics, Inc. in Cambridge, MA, a biotech company that is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis. These novel therapies are designed to treat multiple degenerative disorders such as Alzheimer’s disease, Parkinson's disease, Huntington’s disease, cancer, and type II diabetes.